Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors
Completed · Phase 1
Conditions studied: Non-colorectal Cancer, Pancreatic Cancer
In brief
RATIONALE: Monoclonal antibodies, such as maytansinoid DM4-conjugated humanized monoclonal antibody huC242, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of maytansinoid DM4-conjugated humanized monoclonal antibody huC242 in treating patients with solid tumors that cannot be removed by surgery or have spread to other parts of the body.
Key facts
- Study ID
- NCT00352131
- Run by
- ImmunoGen, Inc.
- People needed
- 50
- Starts
- 2005-02-01
- Expected to finish
- 2009-12-01
- Last updated by the study team
- 2010-03-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- South Texas Accelerated Research Therapeutics — San Antonio, Texas, United States
- UT Health Science Center — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.